The US Food and Drug Administration (FDA) has just approved a game-changing cholesterol drug, the first of its kind in a class that’s otherwise administered by injection. Lipfendra, or enlicitide, blocks the PCSK9 protein, which drives cholesterol levels up and…
Continue reading with a subscription
This article is available to subscribers. Subscribe to read it in full, or sign in if you already have an account.